Personalising the use of chemotherapy in breast cancer treatment

December 15, 2011
Personalising the use of chemotherapy in breast cancer treatment
Manual and automated immunohistochemical analysis of CART expression. Immunohistochemical analysis of primary breast cancer with corresponding markup images of automated algorithm used to quantify CART expression. Stromal tissue is mapped in blue on the markup image, and CART expression is mapped on an increasing scale from yellow (low levels of expression) to red (high levels of expression). For manual analysis, CART expression is in brown, with stromal tissue counterstained in purple.

(Medical Xpress) -- UCD researchers have identified a novel biomarker that can identify those women with breast cancer who will have a poor response to tamoxifen, one of the principle anti-hormone drugs used to treat the disease. This may allow clinicians to tailor the treatment of early stage breast cancer patients appropriately.

Conway Fellow, Professor William Gallagher and his team who form part of the Science Foundation Ireland-funded strategic research cluster, Molecular Therapeutics for Cancer Ireland (MTCI), examined the breast cancers of over 1,000 patients. They found that those with high levels of a protein named CART (cocaine-and-amphetamine-regulated transcript) had a significantly poorer outcome when treated with compared to those patients with zero or low levels of the protein.

Tamoxifen works by blocking the growth-promoting action of oestrogen in cells. The results of this research published in a leading scientific journal, Oncogene, describes how CART can intervene and prevent tamoxifen from killing the cancer cells. Commenting on the findings, Dr Darran O’Connor, senior scientist and joint lead author of the research said, “Identifying early stage breast who need additional chemotherapy is a matter of intense clinical interest. We believe that CART profiling will facilitate the stratification of lymph node-negative breast cancer patients into high- and low-risk categories and allow for the personalisation of therapy.”

Dr Donal Brennan, UCD School of Medicine,  National Maternity Hospital and joint lead author of the work added, “We clearly demonstrate that both pre- and post-menopausal, early stage with high CART expressing tumours have a poor outcome and do not respond well to treatment with tamoxifen. Due to this, we believe that they should receive aggressive adjuvant chemotherapy.”

At present, women diagnosed with early stage, hormone receptor-positive, lymph node-negative breast cancer undergo surgery coupled with anti-hormone therapy and chemotherapy. However, current research suggests that many patients would do equally well with surgery and anti-hormone therapy without the addition of debilitating chemotherapeutic regimens.

The findings of the UCD team, in collaboration with colleagues at Lund University in Sweden, could help clinicians to accurately identify those patients who do not require chemotherapy and for whom surgery and anti-hormone therapy alone is sufficient to treat their cancer. In addition to improving the patients’ quality of life, this can also reduce the economic burden associated with unnecessary supplementary treatment. 

While CART has been widely studied in other areas as a key regulator of body weight and the body’s response to drugs such as cocaine, the researchers are the first to demonstrate a link with breast cancer.

Looking to the future for this research, Professor William Gallagher, associate professor of cancer biology, founder and chief scientific officer of Oncomark, a UCD molecular diagnostics spin-out company said, “As translational researchers, our goal is to bring our findings from the laboratory into the clinic. Our intention now is to develop a clinically approved test so that we can identify those patients who will benefit most from tailoring their therapy based upon the CART status of their cancer”.

Explore further: Another step toward resisting breast cancer

Related Stories

Another step toward resisting breast cancer

September 21, 2011
Medical researchers at the University of Leeds have come a step closer to understanding how to stop breast cancers from coming back.

Marker identifies breast cancer patients likely to respond to tamoxifen

May 18, 2011
Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy.

Male breast cancer patients stop taking tamoxifen early because of drug-related side effects

November 16, 2011
The largest study to investigate the tolerability of the breast cancer drug tamoxifen in male breast cancer patients has shown that men stop taking their prescribed therapy early because of problems with side effects caused ...

New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy

September 26, 2011
Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. Researchers ...

Recommended for you

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.